MILANO (AIMnews.it) - Kolinpharma has today launched the placement of ordinary shares (scheduling to close on February 26th) arising from the capital increase approved by the shareholders' meeting. The price range was set between 6.5 and 7.5 euros, equivalent to a pre-money capitalisation of between 6.5 and 7.5 million. The minimum lot has been set to 200 shares. The start of trading on the Aim Italia market is expected in the first half of March. Kolinpharma is an innovative SME operating in the nutraceutical sector, specialised in research and development: in 2017 it achieved a turnover of about 4 million euros (+ 60% compared to 2016) with an ebitda margin of 15% (+ 45% on 2016). With the listing, the company aims to strengthen and accelerate scientific research and development of new products, as well as grow internally and externally through agreements with other operators or extraordinary transactions, including at international level. Nominated Adviser and Global Coordinator of the transaction is EnVent Capital Markets, IR TOP Consulting for IPO Research and Investor Relations, Directa Sim acts as an online retailer.